Plain-English translation of ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called GPC-3 CAR T cells for people with a type of recurring brain tumor called glioblastoma. Researchers take immune cells from your blood, genetically engineer them in the laboratory to recognize and attack tumor cells, and then place them directly into your brain tumor during surgery. The goal is to see if this approach can help slow or stop the cancer from growing.
Glioblastoma is an aggressive brain cancer that often comes back even after surgery and other treatments. This study exists to see if this medication—which trains your own immune system to fight the cancer—might offer a new option for patients whose tumors have returned.
You likely qualify if…
You likely don't qualify if…
First, researchers will collect a blood sample to grow and genetically engineer your immune cells—a process that takes several weeks. When you are already scheduled for surgery to remove the recurring tumor, the modified cells will be thawed and placed directly into the tumor area during that same surgery. Your surgeon will also place a small tube under your scalp (called an Ommaya reservoir) to monitor how you respond to the treatment and to help manage any brain swelling. You will receive one dose of this treatment and then be followed closely to see how well it works.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States